IMMX · Immix Biopharma, Inc.
$8.44
-0.25 (-2.88%)
At close · Jul 28
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$472.84M
Shares
54.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.44
Open$8.63
Day$8.10–8.84
52W$1.94–12.14
Avg vol 30d2.2M
Short int8.5M · 15.6% float · 4.6d
Short vol41%
DataDec 2021–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+16%
above
Price vs 50-day avg
−10%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
64%
mid-range
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+36%
trailing
YTD return
+61%
this year
Relative strength
+28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
7 of 77 funds reported for Jun 30 · net +22.5K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.62% of float · ▲ +7.9% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
77 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
−17%
Y/Y
Free cash flow
$-24.7M
Balance sheet
$93.9M
net cash
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
9.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+16%
Bullish
Price vs 50-day avg
−10%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
64%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
7 of 77 funds reported for Jun 30 · net +22.5K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.62% of float · ▲ +7.9% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
77 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $8 · 64%
52-wk high $12
vs 200-day avg +16%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMMX
this stock
Immix Biopharma, Inc.
|
$472.84M | +61.4% | — | — | 15.6% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMMX | -4.1% | -15.4% | +35.9% | -18.1% | +61.4% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -3.1% | -15.4% | +28.5% | -17.4% | +52.7% |